Recent performance snapshot

Recursion Pharmaceuticals (RXRX) has drawn investor attention after its share price closed at US$3.01, with the stock down about 19% over the past month and roughly 12% over the past 3 months.

For context, RXRX’s 1-day share price return declined 3.22%, and the 30-day share price return is down 19.30%, while the 1-year total shareholder return has fallen 26.23%. This points to fading momentum after earlier periods of stronger enthusiasm.

If you are weighing RXRX against other opportunities in this space, it can help to broaden your watchlist with a curated set of healthcare focused AI stocks using the 34 healthcare AI stocks.

With RXRX trading at US$3.01 and sitting at a sizeable discount to both certain intrinsic value estimates and analyst targets, the key question is simple: is this weakness a potential opportunity or is the market already accounting for future growth in the current price?

Most Popular Narrative: 52.8% Overvalued

Based on the most followed narrative, RXRX’s fair value is set at $1.97, which sits well below the recent close at $3.01. This creates a wide gap that this view tries to justify.

Recursion Pharmaceuticals (RXRX) one day will be the Palantir of biotechnology! With the CMO transitioning out as well as the former CEO RXRX now has a chance to take off! Vikki Goodman and Najat Khan can now lead RXRX back to respectability and acceptance as a real leader in biotechnology! Once the announcements start coming in on REC-4881 going to Phase 3 and beyond this stock will skyrocket! RXRX finally has the right people in place to do their jobs correctly! Many institutions will soon be coming in with more good news to follow!!!

Curious how a forecasted revenue ramp, optimistic profit margins and a premium future earnings multiple all combine to still argue RXRX is overpriced at today’s level? The full narrative breaks down the assumptions line by line, including what has to happen in the pipeline and on the income statement for $1.97 to make sense.

Result: Fair Value of $1.97 (OVERVALUED)

However, still remember that setbacks in clinical trials or slower than expected adoption of Recursion’s drug discovery platform could quickly challenge this optimistic pricing story.

Another view: DCF points the other way

The user narrative argues RXRX is overvalued at a fair value of $1.97, but the SWS DCF model paints a very different picture. On that approach, RXRX at $3.01 sits well below an estimated future cash flow value of $9.04, suggesting a wide valuation gap. Which story do you think better reflects the risks and rewards here?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Recursion Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 49 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

The split between a cautious narrative and a supportive DCF view highlights how mixed sentiment is around RXRX right now. It makes sense to review the data, weigh both sides, and focus on the fundamentals behind the story by checking the 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If RXRX sits on your watchlist, do not stop there. Use data driven screeners to widen your opportunity set and avoid missing stocks that fit your style.

• Spot potential underpriced opportunities early by scanning companies in the 49 high quality undervalued stocks that combine supportive fundamentals with discounted market prices.
• Strengthen your portfolio core by focusing on businesses in the solid balance sheet and fundamentals stocks screener (46 results) that pair financial resilience with consistent operating profiles.
• Stay ahead of the crowd by checking the screener containing 21 high quality undiscovered gems, where underfollowed stocks with solid foundations may still be off most investors' radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.